Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development.
Becker
Richard C
RC
Divisions of Cardiology and Hematology, Duke University School of Medicine, 2400 Pratt Street, Durham, NC 27705, USA. becke021@mc.duke.edu
D000924:Anticholesteremic Agents / Q000009:adverse effects; D001702:Biopharmaceutics; D002986:Clinical Trials as Topic; D004358:Drug Therapy; D064420:Drug-Related Side Effects and Adverse Reactions; D042783:Endothelial Cells / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D015918:Infusion Pumps, Implantable; D011804:Quinolines / Q000009:adverse effects; D013234:Stem Cells / Q000187:drug effects; D015607:Stents
D000924:Anticholesteremic Agents; D005343:Fibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; C483909:torcetrapib